![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 5.png)
Advantages of hs-cTn Assays Over Conventional Assays
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 6.png)
Compared to conventional assays, hs-cTn assays are associated with the advantages below:1
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-ESC2020-Infographic-2108-Asset 42.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 10.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 10.png)
Higher sensitivity for detection of MI at presentation
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-ESC2020-Infographic-2108-Asset 43.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-ESC2020-Infographic-2108-Asset 43.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-ESC2020-Infographic-2108-Asset 43.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 20.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 20.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 20.png)
Higher negative predictive value for AMI
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-ESC2020-Infographic-2108-Asset 44.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-ESC2020-Infographic-2108-Asset 44.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-ESC2020-Infographic-2108-Asset 44.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 9.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 9.png)
Shorter interval between 2 cTn measurements
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-ESC2020-Infographic-2108-Asset 45.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-ESC2020-Infographic-2108-Asset 45.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-ESC2020-Infographic-2108-Asset 45.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 19.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 19.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 19.png)
Can detect patients whose cTn was undetectable using conventional assays
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 15.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 15.png)
Value of High-Sensitive Cardiac Troponin2
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-ESC2020-Infographic-2108-Asset 42.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-ESC2020-Infographic-2108-Asset 42.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-ESC2020-Infographic-2108-Asset 42.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 20.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 20.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 20.png)
Early detection of MI
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-ESC2020-Infographic-2108-Asset 43.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-ESC2020-Infographic-2108-Asset 43.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-ESC2020-Infographic-2108-Asset 43.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 19.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 19.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 19.png)
Enables more rapid “rule-in” and “rule-out” of MI
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-ESC2020-Infographic-2108-Asset 44.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-ESC2020-Infographic-2108-Asset 44.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-ESC2020-Infographic-2108-Asset 44.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 16.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 16.png)
Increase detection of type 1 MI and type II MI
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-ESC2020-Infographic-2108-Asset 45.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-ESC2020-Infographic-2108-Asset 45.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-ESC2020-Infographic-2108-Asset 45.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 17.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 17.png)
Decrease diagnosis of unstable angina
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 26.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 26.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 18.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 18.png)
Higher accuracy at the exact low cost
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 22.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 22.png)
A Quantitative Marker for Cardiomyocyte Damage
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset-21-new.png.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset-21-new.png.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset-21-new.png.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset-21-new.png.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset-21-new.png.png)
hs-cTn assays can detect cardiac troponin in a significant portion of healthy population.1
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset-21-new.png.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset-21-new.png.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset-21-new.png.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset-21-new.png.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset-21-new.png.png)
Apart from MI, there are several other conditions that can be associated with increased cTn levels.1
Conditions Other Than Acute Type 1 MI Associated with Myocardial Injury Causing cTn Elevations1
Tachyarrhythmias, heart failure, hypertensive emergencies, critical illness, myocarditis, Takotsubo syndrome, valvular heart disease, aortic dissection and pulmonary embolism
In elderly patients with renal dysfunction, chronic coronary syndromes or hypertensive heart disease are the most frequent causes of elevated cardiac troponin concentration
Assessing the rise and/or fall of cTn levels can help differentiate MI from other conditions associated with cardiomyocyte injury1,3
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset-25.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset-25.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 25.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset 25.png)
High Throughput Laboratory Assays vs. POCT
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset-21-new.png.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset-21-new.png.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset-21-new.png.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset-21-new.png.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset-21-new.png.png)
Cardiac troponin assays that are run on automated platforms are mostly sensitive or high-sensitivity assays.1
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset-21-new.png.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset-21-new.png.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset-21-new.png.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset-21-new.png.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-hs-cTn-Assays-Infographic-2108-Asset-21-new.png.png)
Most of the POCTs in current use are not considered sensitive or high-sensitivity assays.
Automated assays are preferred.1
ESC 2020 does not recommend the use of biomarkers such as CK, CK-MB, h-FABP, or copeptin, in addition to hs-cTn.1
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-ESC2020-Infographic-2108-Asset 20.png)
![](https://dianews.roche.com/rs/106-RRW-330/images/CTL-ESC2020-Infographic-2108-Asset 20.png)